Skip to main content

Iterum Therapeutics to Present Data at ASM Microbe 2023

Written by Customer Service on . Posted in Public Companies.

DUBLIN, Ireland and CHICAGO, June 12, 2023 (GLOBE NEWSWIRE) — Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that three posters will be presented at ASM Microbe 2023 conference.

The hybrid conference will be held from June 15-19 at the George R. Brown Convention Center in Houston, TX.

Data to be presented include:

Presentation title: β-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Uncomplicated Urinary Tract Infection

Presentation type/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; β-lactamases (AAR-Friday-410)
Presenter: Steven I. Aronin, MD
Time/location: June 16, 2023, 10:00 a.m. – 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D

Presentation title: β-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Complicated Urinary Tract Infection

Presentation type/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; β-lactamases (AAR-Friday-417)
Presenter: Sailaja Puttagunta, MD
Time/location: June 16, 2023, 10:00 a.m. – 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D

Presentation title: β-Lactamase Characterization of Baseline Enterobacterales Pathogens from a Phase 3 Trial of Sulopenem for the Treatment of Complicated Intraabdominal Infection

Presentation type/category: P002-AAR01 Surveillance of antimicrobial resistance in clinical isolates; β-lactamases (AAR-Friday-401)
Presenter: Sailaja Puttagunta, MD
Time/location: June 16, 2023, 10:00 a.m. – 5:00 p.m. CDT; Exhibit and Poster Hall B, C, D

These Posters will be made available on the Company’s website on the “Publications: Posters & Presentations” page under the “Our Science” tab once the conference ends.

About Iterum Therapeutics plc

Iterum Therapeutics plc is a clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Investor Contact:
Judy Matthews
Chief Financial Officer
312-778-6073
IR@iterumtx.com 

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.